Molecular OncologyPub Date : 2022-09-01Epub Date: 2022-06-19DOI: 10.1002/1878-0261.13261
Stanislav Drapela, Didem Ilter, Ana P Gomes
{"title":"Metabolic reprogramming: a bridge between aging and tumorigenesis.","authors":"Stanislav Drapela, Didem Ilter, Ana P Gomes","doi":"10.1002/1878-0261.13261","DOIUrl":"10.1002/1878-0261.13261","url":null,"abstract":"<p><p>Aging is the most robust risk factor for cancer development, with more than 60% of cancers occurring in those aged 60 and above. However, how aging and tumorigenesis are intertwined is poorly understood and a matter of significant debate. Metabolic changes are hallmarks of both aging and tumorigenesis. The deleterious consequences of aging include dysfunctional cellular processes, the build-up of metabolic byproducts and waste molecules in circulation and within tissues, and stiffer connective tissues that impede blood flow and oxygenation. Collectively, these age-driven changes lead to metabolic reprogramming in different cell types of a given tissue that significantly affects their cellular functions. Here, we put forward the idea that metabolic changes that happen during aging help create a favorable environment for tumorigenesis. We review parallels in metabolic changes that happen during aging and how these changes function both as adaptive mechanisms that enable the development of malignant phenotypes in a cell-autonomous manner and as mechanisms that suppress immune surveillance, collectively creating the perfect environment for cancers to thrive. Hence, antiaging therapeutic strategies that target the metabolic reprogramming that occurs as we age might provide new opportunities to prevent cancer initiation and/or improve responses to standard-of-care anticancer therapies.</p>","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"3295-3318"},"PeriodicalIF":4.5,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42508530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a β2AR-Akt feedback loop that activates autophagy.","authors":"Xin Chen, Weifan Zhang, Rujuan Liu, Zeen Zhu, Mengyuan Gong, Qiqi Wang, Weikun Qian, Zheng Wu, Qingyong Ma, Zheng Wang","doi":"10.1002/1878-0261.13230","DOIUrl":"10.1002/1878-0261.13230","url":null,"abstract":"<p><p>Low responsiveness to chemotherapy is an important cause of poor prognosis in pancreatic cancer. Smoking is a high-risk factor for pancreatic cancer and cancer resistance to gemcitabine; however, the underlying mechanisms remain unclear. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is the main metabolite of tobacco burning and has been shown to be associated with cancer development and chemoresistance. However, in pancreatic cancer, its mechanism remains poorly understood. In this study, we found that NNK promoted stemness and gemcitabine resistance in pancreatic cancer cell lines. Moreover, NNK increased autophagy and elevated the expression levels of the autophagy-related markers autophagy-related gene 5 (ATG5), autophagy-related gene 7 (ATG7), and Beclin1. Furthermore, the results showed that NNK-promoted stemness and gemcitabine resistance was partially dependent on the role of NNK in cell autophagy, which is mediated by the β2-adrenergic receptor (β2AR)-Akt axis. Finally, we proved that NNK intervention could not only activate β2AR, but also increase its expression, making β2AR and Akt form a feedback loop. Overall, these findings show that the NNK-induced β2AR-Akt feedback loop promotes stemness and gemcitabine resistance in pancreatic cancer cells.</p>","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"2881-2895"},"PeriodicalIF":4.5,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46647794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular OncologyPub Date : 2022-08-01Epub Date: 2022-06-27DOI: 10.1002/1878-0261.13259
Min Liu, Runmei Li, Min Wang, Ting Liu, Qiuru Zhou, Dong Zhang, Jian Wang, Meng Shen, Xiubao Ren, Qian Sun
{"title":"PGAM1 regulation of ASS1 contributes to the progression of breast cancer through the cAMP/AMPK/CEBPB pathway.","authors":"Min Liu, Runmei Li, Min Wang, Ting Liu, Qiuru Zhou, Dong Zhang, Jian Wang, Meng Shen, Xiubao Ren, Qian Sun","doi":"10.1002/1878-0261.13259","DOIUrl":"10.1002/1878-0261.13259","url":null,"abstract":"<p><p>Phosphoglycerate mutase 1 (PGAM1) is a crucial glycolytic enzyme, and its expression status has been confirmed to be associated with tumor progression and metastasis. However, the precise role and other biological functions of PGAM1 remain unclear. Here, we report that PGAM1 expression is upregulated and related to poor prognosis in patients with breast cancer (BC). Functional experiments showed that knockdown of PGAM1 could suppress the proliferation, invasion, migration, and epithelial-mesenchymal transition of BC cells. Through RNA sequencing, we found that argininosuccinate synthase 1 (ASS1) expression was markedly upregulated in BC cells following PGAM1 knockdown, and it is required to suppress the malignant biological behavior of BC cells. Importantly, we demonstrated that PGAM1 negatively regulates ASS1 expression through the cAMP/AMPK/CEBPB axis. In vivo experiments further validated that PGAM1 promoted tumor growth in BC by altering ASS1 expression. Finally, immunohistochemical analysis showed that downregulated ASS1 levels were associated with PGAM1 expression and poor prognosis in patients with BC. Our study provides new insight into the regulatory mechanism of PGAM1-mediated BC progression that might shed new light on potential targets and combination therapeutic strategies for BC treatment.</p>","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"2843-2860"},"PeriodicalIF":4.5,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43392142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular OncologyPub Date : 2022-08-01Epub Date: 2022-06-14DOI: 10.1002/1878-0261.13255
Kavya Ganapathy, Christopher Ngo, Thomas Andl, Domenico Coppola, Jong Park, Ratna Chakrabarti
{"title":"Anticancer function of microRNA-30e is mediated by negative regulation of HELLPAR, a noncoding macroRNA, and genes involved in ubiquitination and cell cycle progression in prostate cancer.","authors":"Kavya Ganapathy, Christopher Ngo, Thomas Andl, Domenico Coppola, Jong Park, Ratna Chakrabarti","doi":"10.1002/1878-0261.13255","DOIUrl":"10.1002/1878-0261.13255","url":null,"abstract":"<p><p>Prostate cancer (PCa) progression relies on androgen receptor (AR) function, making AR a top candidate for PCa therapy. However, development of drug resistance is common, which eventually leads to development of castration-resistant PCa. This warrants a better understanding of the pathophysiology of PCa that facilitates the aberrant activation of key signaling pathways including AR. MicroRNAs (miRNAs) function as regulators of cancer progression as they modulate various cellular processes. Here, we demonstrate a multidimensional function of miR-30e through the regulation of genes involved in various signaling pathways. We noted loss of miR-30e expression in prostate tumors, which, when restored, led to cell cycle arrest, induction of apoptosis, improved drug sensitivity of PCa cells and reduced tumor progression in xenograft models. We show that experimental upregulation of miR-30e reduces expression of mRNAs including AR, FBXO45, SRSF7 and MYBL2 and a novel long noncoding RNA (lncRNA) HELLPAR, which are involved in cell cycle, apoptosis and ubiquitination, and the effects could be rescued by inhibition of miR-30e expression. RNA immunoprecipitation analysis confirmed direct interactions between miR-30e and its RNA targets. We noted a newly identified reciprocal relationship between miR-30e and HELLPAR, as inhibition of HELLPAR improved stabilization of miR-30e. Transcriptome profiling and quantitative real-time PCR (qRT-PCR) validation of miR-30e-expressing PCa cells showed differential expression of genes involved in cell cycle progression, apoptosis and ubiquitination, which supports our in vitro study. This study demonstrates an integrated function of miR-30e on dysregulation of miRNA/lncRNA/mRNA axes that may have diagnostic and therapeutic significance in aggressive PCa.</p>","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"2936-2958"},"PeriodicalIF":4.5,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47799125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular OncologyPub Date : 2022-08-01Epub Date: 2022-06-18DOI: 10.1002/1878-0261.13225
Susanne G Kidd, Mari Bogaard, Kristina T Carm, Anne Cathrine Bakken, Aase M V Maltau, Marthe Løvf, Ragnhild A Lothe, Karol Axcrona, Ulrika Axcrona, Rolf I Skotheim
{"title":"In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis.","authors":"Susanne G Kidd, Mari Bogaard, Kristina T Carm, Anne Cathrine Bakken, Aase M V Maltau, Marthe Løvf, Ragnhild A Lothe, Karol Axcrona, Ulrika Axcrona, Rolf I Skotheim","doi":"10.1002/1878-0261.13225","DOIUrl":"10.1002/1878-0261.13225","url":null,"abstract":"<p><p>Prognostic biomarkers for prostate cancer are needed to improve prediction of disease course and guide treatment decisions. However, biomarker development is complicated by the common multifocality and heterogeneity of the disease. We aimed to determine the prognostic value of candidate biomarkers transcriptional regulator ERG and related ETS family genes, while considering tumor heterogeneity. In a multisampled, prospective, and treatment-naïve radical prostatectomy cohort from one tertiary center (2010-2012, median follow-up 8.1 years), we analyzed ERG protein (480 patients; 2047 tissue cores), and RNA of several ETS genes in a subcohort (165 patients; 778 fresh-frozen tissue samples). Intra- and interfocal heterogeneity was identified in 29% and 33% (ERG protein) and 39% and 27% (ETS RNA) of patients, respectively. ERG protein and ETS RNA was identified exclusively in a nonindex tumor in 31% and 32% of patients, respectively. ERG protein demonstrated independent prognostic value in predicting biochemical (P = 0.04) and clinical recurrence (P = 0.004) and appeared to have greatest prognostic value for patients with Grade Groups 4-5. In conclusion, when heterogeneity is considered, ERG protein is a robust prognostic biomarker for prostate cancer.</p>","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"2810-2822"},"PeriodicalIF":4.5,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46129252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular OncologyPub Date : 2022-07-01Epub Date: 2022-06-27DOI: 10.1002/1878-0261.13267
Daan C L Vessies, Milou M F Schuurbiers, Vincent van der Noort, Irene Schouten, Theodora C Linders, Mirthe Lanfermeijer, Kalpana L Ramkisoensing, Koen J Hartemink, Kim Monkhorst, Michel M van den Heuvel, Daan van den Broek
{"title":"Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients.","authors":"Daan C L Vessies, Milou M F Schuurbiers, Vincent van der Noort, Irene Schouten, Theodora C Linders, Mirthe Lanfermeijer, Kalpana L Ramkisoensing, Koen J Hartemink, Kim Monkhorst, Michel M van den Heuvel, Daan van den Broek","doi":"10.1002/1878-0261.13267","DOIUrl":"10.1002/1878-0261.13267","url":null,"abstract":"<p><p>Stage II-IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy after surgery as standard-of-care treatment, even though only approximately 5.8% of patients will benefit. Identifying patients with minimal residual disease (MRD) after surgery using tissue-informed testing of postoperative plasma circulating cell-free tumour DNA (ctDNA) may allow adjuvant therapy to be withheld from patients without MRD. However, the detection of MRD in the postoperative setting is challenging, and more sensitive methods are urgently needed. We developed a method that combines variant calling and a novel ctDNA fragment length analysis using hybrid capture sequencing data. Among 36 stage II-IIIA NSCLC patients, this method distinguished patients with and without recurrence of disease in a 20 times repeated 10-fold cross validation with 75% accuracy (P = 0.0029). In contrast, using only variant calling or only fragment length analysis, no signification distinction between patients was shown (P = 0.24 and P = 0.074 respectively). In addition, a variant-level fragmentation score was developed that was able to classify variants detected in plasma cfDNA into tumour-derived or white-blood-cell-derived variants with 84% accuracy. The findings in this study may help drive the integration of various types of information from the same data, eventually leading to cheaper and more sensitive techniques to be used in this challenging clinical setting.</p>","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"2719-2732"},"PeriodicalIF":5.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49047359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular OncologyPub Date : 2022-07-01Epub Date: 2022-04-08DOI: 10.1002/1878-0261.13202
Bryan H Louie, Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Suzanna Lee, Ryosuke Okamura, Paul T Fanta, Razelle Kurzrock
{"title":"Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience.","authors":"Bryan H Louie, Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Suzanna Lee, Ryosuke Okamura, Paul T Fanta, Razelle Kurzrock","doi":"10.1002/1878-0261.13202","DOIUrl":"10.1002/1878-0261.13202","url":null,"abstract":"<p><p>Treatment for advanced colorectal cancer is often limited by complex molecular profiles, which promote resistance to systemic agents and targeted monotherapies. Recent studies suggest that a personalized, combinatorial approach of matching drugs to tumor alterations may be more effective. We implemented a precision medicine strategy by forming a Molecular Tumor Board (MTB), a multidisciplinary team of clinicians, scientists, bioinformaticians and geneticists. The MTB integrated molecular profiling information and patient characteristics to develop N-of-One treatments for 51 patients with advanced colorectal cancer. All patients had metastatic disease and 63% had received ≥ 3 prior therapy lines. Overall, 34/51 patients (67%) were matched to ≥ 1 drug recommended by the MTB based on individual tumor characteristics, whereas 17/51 (33%) patients received unmatched therapies. Patients who received matched therapy demonstrated significantly longer progression-free survival (hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.21-0.81; P = 0.01) and a trend towards higher clinical benefit rates (41% vs. 18%, P = 0.058) (all multivariate) compared to patients receiving unmatched therapy. The MTB facilitated personalized matching of drugs to tumor characteristics, which was associated with improved progression-free survival in patients with advanced colorectal cancer.</p>","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"2575-2584"},"PeriodicalIF":4.5,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45852499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Classon, Margherita Zamboni, Camilla Engblom, K. Alkass, G. Mantovani, Christian Pou, Dieudonné Nkulikiyimfura, P. Brodin, H. Druid, Jeff E. Mold, J. Frisén
{"title":"Prostate cancer disease recurrence after radical prostatectomy is associated with HLA type and local cytomegalovirus immunity","authors":"J. Classon, Margherita Zamboni, Camilla Engblom, K. Alkass, G. Mantovani, Christian Pou, Dieudonné Nkulikiyimfura, P. Brodin, H. Druid, Jeff E. Mold, J. Frisén","doi":"10.1002/1878-0261.13273","DOIUrl":"https://doi.org/10.1002/1878-0261.13273","url":null,"abstract":"Prostate cancer is a heterogeneous disease with a need for new prognostic biomarkers. Human leukocyte antigen (HLA) genes are highly polymorphic genes central to antigen presentation to T‐cells. Two alleles, HLA‐A*02:01 and HLA‐A*24:02, have been associated with prognosis in patients diagnosed with de novo metastatic prostate cancer. We leveraged the next‐generation sequenced cohorts CPC‐GENE and TCGA‐PRAD to examine HLA alleles, antiviral T‐cell receptors and prostate cancer disease recurrence after prostatectomy. Carrying HLA‐A*02:01 (111/229; 48% of patients) was independently associated with disease recurrence in patients with low‐intermediate risk prostate cancer. HLA‐A*11 (carried by 42/441; 10% of patients) was independently associated with rapid disease recurrence in patients with high‐risk prostate cancer. Moreover, HLA‐A*02:01 carriers in which anti‐cytomegalovirus T‐cell receptors (CMV‐TCR) were identified in tumors (13/144; 10% of all patients in the cohort) had a higher risk of disease recurrence than CMV‐TCR‐negative patients. These findings suggest that HLA‐type and CMV immunity may be valuable biomarkers for prostate cancer progression.","PeriodicalId":51134,"journal":{"name":"Molecular Oncology","volume":"16 1","pages":"3452 - 3464"},"PeriodicalIF":6.6,"publicationDate":"2022-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48045198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}